These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2342197)

  • 21. Experimental intravesical therapy for superficial transitional cell carcinoma in a rat bladder tumor model.
    Steinberg GD; Brendler CB; Squire RA; Isaacs JT
    J Urol; 1991 Mar; 145(3):647-53. PubMed ID: 1997724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study.
    Torti FM; Shortliffe LD; Williams RD; Pitts WC; Kempson RL; Ross JC; Palmer J; Meyers F; Ferrari M; Hannigan J
    J Clin Oncol; 1988 Mar; 6(3):476-83. PubMed ID: 3280742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder.
    Cervenakov I; Szoldova K; Mardiak J; Chovan D; Mala M; Slavov D
    Bratisl Lek Listy; 2000; 101(6):317-20. PubMed ID: 11039202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration.
    Dinney CP; Bielenberg DR; Perrotte P; Reich R; Eve BY; Bucana CD; Fidler IJ
    Cancer Res; 1998 Feb; 58(4):808-14. PubMed ID: 9485039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer.
    Adam L; Black PC; Kassouf W; Eve B; McConkey D; Munsell MF; Benedict WF; Dinney CP
    J Urol; 2007 May; 177(5):1900-6. PubMed ID: 17437845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells.
    Derycke AS; Kamuhabwa A; Gijsens A; Roskams T; De Vos D; Kasran A; Huwyler J; Missiaen L; de Witte PA
    J Natl Cancer Inst; 2004 Nov; 96(21):1620-30. PubMed ID: 15523091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
    Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flow cytometry correlates of response to intravesical interferon.
    Bonney WW; Rosenberg SJ; Kluskens LF; Yen A; Henry KM; Williams RD
    Prog Clin Biol Res; 1988; 260():203-14. PubMed ID: 3362880
    [No Abstract]   [Full Text] [Related]  

  • 29. Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy.
    Agarwal A; Agrawal U; Verma S; Mohanty NK; Saxena S
    Immunopharmacol Immunotoxicol; 2010 Jun; 32(2):348-56. PubMed ID: 20105083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model.
    Horiguchi Y; Larchian WA; Kaplinsky R; Fair WR; Heston WD
    Gene Ther; 2000 May; 7(10):844-51. PubMed ID: 10845722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer.
    Russell PJ; Plomley J; Shon IH; O'Grady H; Pearce N
    Cell Biophys; 1993; 22(1-3):27-47. PubMed ID: 7889541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concomitant treatment of MBT-2 bladder tumour by tumour necrosis factor alpha and interferon alpha in conjunction with delayed type hypersensitivity immunotherapy.
    Kadhim SA; Chin JL
    Urol Res; 1991; 19(1):57-62. PubMed ID: 1674182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation by the protein-bound polysaccharide PSK (krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer.
    Mizutani Y; Yoshida O
    J Urol; 1991 May; 145(5):1082-7. PubMed ID: 2016797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immobilization of streptavidin-tagged bioactive hTNF-alpha on biotinylated mucosal surface of the bladder wall for treatment of superficial bladder cancer in mice].
    Chen Z; Tan WL; Huang X; Liang ZK; Xu CX; Gao JM
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):936-40. PubMed ID: 20501361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
    Izawa JI; Sweeney P; Perrotte P; Kedar D; Dong Z; Slaton JW; Karashima T; Inoue K; Benedict WF; Dinney CP
    Clin Cancer Res; 2002 Apr; 8(4):1258-70. PubMed ID: 11948141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of liposome-encapsulated alpha- or beta-interferon on breast cancer cell lines.
    Coradini D; Pellizzaro C; Biffi A; Lombardi L; Pirronello E; Riva L; Di Fronzo G
    Anticancer Res; 1998; 18(1A):177-82. PubMed ID: 9568074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Localization of IL-1, IL-2, IL-4, IL-8 and TNF in superficial bladder tumors treated with intravesical bacillus Calmette-Guerin.
    Sander B; Damm O; Gustafsson B; Andersson U; Håkansson L
    J Urol; 1996 Aug; 156(2 Pt 1):536-41. PubMed ID: 8683732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravesical therapy for superficial bladder cancer.
    Malkowicz SB
    Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of the effect of intravesical treatment with interferon-alpha 2b on the clinical evolution and on the in vivo function of T lymphocytes and natural killer cells in patients with superficial bladder tumors.
    Carballido J; Moltó LM; Olivier C; Manzano L; Alvarez-Mon M
    Anticancer Drugs; 1992 May; 3 Suppl 1():9-12. PubMed ID: 1611118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
    Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
    J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.